All terms in NCIT
| Label | Id | Description |
|---|---|---|
| MED27 Gene | NCIT_C20690 | [This gene is involved in the transcriptional activation of Sp1.] |
| TSQM Version 1.4 - Convenient or Inconvenient Take Medication | NCIT_C132628 | [Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How convenient or inconvenient is it to take the medication as instructed?] |
| TSQM Version 1.4 - Confident Medication Is Good for You | NCIT_C132629 | [Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) Overall, how confident are you that taking this medication is a good thing for you?] |
| C-X-C Motif Chemokine 13 | NCIT_C29030 | [C-X-C motif chemokine 13 (109 aa, ~13 kDa) is encoded by the human CXCL13 gene. This protein is involved in chemotaxis of B-cells.] |
| Head and Neck Cancer pNX TNM Finding v8 | NCIT_C132644 | [Head and neck cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)] |
| C-X-C Motif Chemokine 14 | NCIT_C29031 | [C-X-C motif chemokine 14 (111 aa, ~13 kDa) is encoded by the human CXCL14 gene. This protein plays a role in chemoattraction for neutrophils, and dendritic cells.] |
| Head and Neck Cancer pN0 TNM Finding v8 | NCIT_C132645 | [Head and neck cancer in which no regional lymph node metastases are detected. (from AJCC 8th Ed.)] |
| Esomeprazole Magnesium | NCIT_C29032 | [The magnesium salt of esomeprazole, the S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulphenamide; the active sulphenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.] |
| Head and Neck Cancer pN1 TNM Finding v8 | NCIT_C132646 | [Head and neck cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). (from AJCC 8th Ed.)] |
| Ethambutol Hydrochloride | NCIT_C29033 | [The hydrochloride salt form of ethambutol, an ethylenediamine derivative with antibacterial activity, specifically effective against mycobacteria. Although the exact mechanism of action of ethambutol hydrochloride is unknown, ethambutol hydrochloride inhibits the transfer of mycolic acids into the cell wall of bacteria, which impedes bacterial cell growth. This agent may also interfere with RNA synthesis or inhibit other cell metabolism, thereby preventing cell multiplication and causing cell death.] |
| Ethinyl Estradiol/Levonorgestrel | NCIT_C29034 | [A combination of two steroid sex hormones, an estrogen and a progestin, used for contraceptive purposes. Estradiol, the endogenous counterpart of ethinyl estradiol (EE), is the principal, most potent estrogen hormone produced by the ovaries and is vital to the maintenance of fertility and secondary sexual characteristics in females. Levonorgestrel is a synthetic progestogen. This drug combination prevents or delays ovulation and causes a variety of hormonal changes. Ethinyl estradiol inhibits the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicle; levonorgestrel inhibits the release of luteinizing hormone (LH), thus preventing ovulation. This combination of agents alters the endometrium in such a way as to discourage implantation. (NCI04)] |
| Head and Neck Cancer pN2a TNM Finding v8 | NCIT_C132648 | [Head and neck cancer with metastasis in a single ipsilateral lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)] |
| Ethinyl Estradiol/Norethindrone | NCIT_C29035 | [An oral contraceptive formulation containing the semisynthetic estrogen, ethinyl estradiol, combined with the synthetic progestin, norethindrone, with estrogenic and progestogenic activities, respectively. Ethinyl estradiol binds to and activates intracellular estrogen receptors found in the reproductive tract and other estrogen-responsive tissues. The activated complex enters the nucleus, binds to the estrogen response elements on DNA, activates the transcription of genes involved in the maintenance of the female reproductive system, inhibits the release of follicle stimulating hormone (FSH) from the anterior pituitary, and suppresses the development of the ovarian follicle. Norethindrone binds to intracellular progesterone receptors in progesterone-responsive tissues, such as the pituitary and those found in the reproductive system, and the activated ligand/receptor complex interacts with specific progesterone response elements on DNA, which results in the alteration in protein synthesis, the inhibition of ovulation, an increase in cervical mucus production, the induction of the secretory phase of the endometrial cycle, and the inhibition of luteinizing hormone (LH) release. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system and alters the structure of the endometrium to discourage implantation.] |
| Head and Neck Cancer pN2b TNM Finding v8 | NCIT_C132649 | [Head and neck cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); (from AJCC 8th Ed.)] |
| NCOA3 Gene | NCIT_C20699 | [This gene plays a role in regulation of transcription.] |
| Histone Acetylation | NCIT_C20740 | [Histone Acetylation involves covalent linkage of acetyl groups to highly basic histone proteins associated with DNA, particularly in active chromatin, and may be involved in regulation of gene expression.] |
| Etretinate | NCIT_C29036 | [A synthetic oral retinoid that is a prodrug of acitretin. Etretinate activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells. Etretinate is no longer commercially available in the U.S. due to the extended potential for teratogenic effects related to its long half-life. (NCI04)] |
| Ex-Lax | NCIT_C29037 | [A commercial preparation, by Novartis, with laxative activity. Ex-Lax contains anthraquinone glycosides sennosides, extracted from senna leaves. Sennosides irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions that lead to vigorous bowel movement and relief constipation.] |
| Acetaminophen/Aspirin/Caffeine | NCIT_C29038 | [A commercial combination preparation by Novartis containing acetaminophen, aspirin, and caffeine with analgesic activity. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis while aspirin, a salicylate, inhibits cyclooxygenases (COX) with anti-inflammatory, antipyretic and analgesic properties. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. Excedrin is used for the relief and treatment of migraine and tension headaches.] |
| FDG | NCIT_C29039 |